- In a statement, Allergan (NYSE:AGN -0.3%) says splitting the Chairman and CEO roles currently held by Brent Saunders, a change advocated by institutional shareholder Appaloosa LP, would be "highly disruptive" to the company and "diminish Mr. Saunders' ability to execute Allergan's strategy" to create a world-class business.
- Throwing Appaloosa a bone, the company "supports" splitting the roles with the next leadership change.